Generative Biology
A fundamental shift in therapeutic development, driven by machine intelligence.
What if… We could generate novel protein therapeutics using new computational tools, without having to discover them through trial and error?
Now we can.
We’ve put technology to work to understand proteins in ways we never could before.
It turns out… Machine learning algorithms can generate novel sequences for proteins that have never been seen in nature.
By training The Generate Platform on the entire compendium of protein structures and sequences found in nature—supplemented with proprietary experimental data—we can learn the generalizable rules by which a linear amino acid sequence encodes protein structure and function.
Using what we’ve learned, we can create entirely new proteins and modalities that expand our ability to treat disease and solve complex biological challenges. This process drastically increases the success rate of and reduces the time required for drug discovery.
We call this innovation generative biology.
Generating proteins unlike anything that exists today.
Our machine learning algorithms analyze hundreds of millions of known proteins, looking for statistical patterns linking amino acid sequence, structure, and function.
Using these learned statistical patterns, we generate custom protein therapeutics—from short peptides to complex antibodies, enzymes, gene therapies, and yet-to-be-described protein compositions.
Responsible Use of AI
We are pioneering the field of generative biology: a revolutionary approach to drug development that allows us to program protein-based modalities for the first time. As pioneers in this emerging field, we believe it is essential to guide responsible use of AI and emerging technologies, continually monitor and examine the impact of our initiatives and developments in our field, and communicate the implications of our research.
Generate:Biomedicines is committed to the responsible stewardship of AI/ML approaches and recognizes the potential value of clear regulatory frameworks to help guide the further development and use of this technology over time. We routinely monitor and engage in dialogue with policymakers, government officials, academics and industry colleagues to share our perspective and experience, with the goal of informing the conversation and any decisions about use of a powerful technology that we believe can have a tremendous impact on human health. Several senior members of our Generate community are individual signatories to the Community Values, Guiding Principles, and Commitments for the Responsible Development of AI for Protein Design, which originated from public/private sector discussions late in 2023 and was advanced by Responsible AI x Biodesign.
We will remain active and engaged members of the generative AI community, continually assessing best practice, evolving frameworks and working to ensure that human health benefits from the responsible application of one of the most powerful technologies of our lifetime.
Shown below: Our process—from observation to analysis to the generation of novel proteins.